Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.
Saved in:
| Title: | Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. |
|---|---|
| Authors: | Johnson JS; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Miller JW; USF Health Morsani College of Medicine, Tampa, FL, USA., Hatoum F; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Schell MJ; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Yu X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Roman Souza G; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Mizelle S; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Gullapalli K; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Fazili A; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Jain R; Department of Genitourinary Oncology, Weill Cornell Medicine, New York, NY, USA., Chatzkel J; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cen L; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Dhillon J; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cubitt C; Immune Monitoring Core, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Yao J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Whiting J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Li J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Swank J; Department of Pharmacy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Jameel G; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Zhang J; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Wang X; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Fishman M; USF Health Morsani College of Medicine, Tampa, FL, USA.; Tampa General Hospital Cancer Institute, Tampa, FL, USA., Chahoud J; Department of Genitourinary Oncology, Orlando Health Cancer Institute, Orlando, FL, USA. Jad.Chahoud@orlandohealth.com. |
| Source: | Nature communications [Nat Commun] 2026 May 25; Vol. 17 (1). Date of Electronic Publication: 2026 May 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42185255 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Johnson+JS%22">Johnson JS</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Miller+JW%22">Miller JW</searchLink>; USF Health Morsani College of Medicine, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Hatoum+F%22">Hatoum F</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Schell+MJ%22">Schell MJ</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Yu+X%22">Yu X</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Roman+Souza+G%22">Roman Souza G</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Mizelle+S%22">Mizelle S</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Gullapalli+K%22">Gullapalli K</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Fazili+A%22">Fazili A</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Jain+R%22">Jain R</searchLink>; Department of Genitourinary Oncology, Weill Cornell Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chatzkel+J%22">Chatzkel J</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Cen+L%22">Cen L</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Dhillon+J%22">Dhillon J</searchLink>; Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Cubitt+C%22">Cubitt C</searchLink>; Immune Monitoring Core, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Yao+J%22">Yao J</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Whiting+J%22">Whiting J</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Swank+J%22">Swank J</searchLink>; Department of Pharmacy, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Jameel+G%22">Jameel G</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Spiess+PE%22">Spiess PE</searchLink>; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Fishman+M%22">Fishman M</searchLink>; USF Health Morsani College of Medicine, Tampa, FL, USA.; Tampa General Hospital Cancer Institute, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Chahoud+J%22">Chahoud J</searchLink>; Department of Genitourinary Oncology, Orlando Health Cancer Institute, Orlando, FL, USA. Jad.Chahoud@orlandohealth.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2026 May 25; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 May 25. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42185255 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41467-026-73336-1 Languages: – Code: eng Text: English Titles: – TitleFull: Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Johnson JS – PersonEntity: Name: NameFull: Miller JW – PersonEntity: Name: NameFull: Hatoum F – PersonEntity: Name: NameFull: Schell MJ – PersonEntity: Name: NameFull: Yu X – PersonEntity: Name: NameFull: Roman Souza G – PersonEntity: Name: NameFull: Mizelle S – PersonEntity: Name: NameFull: Gullapalli K – PersonEntity: Name: NameFull: Fazili A – PersonEntity: Name: NameFull: Jain R – PersonEntity: Name: NameFull: Chatzkel J – PersonEntity: Name: NameFull: Cen L – PersonEntity: Name: NameFull: Dhillon J – PersonEntity: Name: NameFull: Cubitt C – PersonEntity: Name: NameFull: Yao J – PersonEntity: Name: NameFull: Whiting J – PersonEntity: Name: NameFull: Li J – PersonEntity: Name: NameFull: Swank J – PersonEntity: Name: NameFull: Jameel G – PersonEntity: Name: NameFull: Zhang J – PersonEntity: Name: NameFull: Wang X – PersonEntity: Name: NameFull: Spiess PE – PersonEntity: Name: NameFull: Fishman M – PersonEntity: Name: NameFull: Chahoud J IsPartOfRelationships: – BibEntity: Dates: – D: 25 M: 05 Text: 2026 May 25 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2041-1723 Numbering: – Type: volume Value: 17 – Type: issue Value: 1 Titles: – TitleFull: Nature communications Type: main |
| ResultId | 1 |
